Category: Meridian Bioscience Inc.
After suffering a tough quarter, Meridian Bioscience Inc. acquires the outstanding capital stock of Bioline Ltd., a manufacturer and distributor of molecular biology reagents, for $23.3 million in cash.
By Mary Vanac
Meridian Bioscience Inc. (NSDQ:VIVO) acquired the outstanding capital stock of Bioline Ltd., the London, U.K.-based maker and distributor of molecular biology reagents, for $23.3 million in cash.
The company also said Tuesday its profits fell 24 percent in its third quarter from a year ago, because of continuing weakness in respiratory disease test sales caused by a lack of a flu season and competition for sales of C. difficile tests.
Meridian Bioscience Inc. gets Food & Drug Administration nod to begin selling its first molecular test: illumigene C. difficile.
By Mary Vanacc
Diagnostics company Meridian Bioscience Inc. (NSDQ:VIVO) received the go-ahead from the Food & Drug Administration to sell its first molecular test — illumigene C. difficile.
The Cincinnati life science company has has success making diagnostic test kits that detect pathogens like C. difficile which is a bacterium that can cause diarrhea and, in severe cases, a life-threatening inflammation of the colon.
Meridian Bioscience Inc. inks a world-wide product development and distribution agreement with Italy-based DiaSorin S.p.A. giving the Ohio company access to Eastern Europe and Asia.
By Mary Vanac
Meridian Bioscience Inc. (NSDQ:VIVO) struck an exclusive, world-wide product development and distribution agreement with an Italian diagnostics company that is likely to open doors to new customers in Eastern Europe and Asia.
Meridian Bioscience applies for the Food & Drug Administration's OK to market a genetic test for C. difficile bacteria.
By Brandon Glenn
Meridian Bioscience (NSDQ:VIVO) applied for federal regulatory approval of a next-generation molecular test that detects a type of bacteria that causes damage to the digestive system.
Stock prices for Meridian Bioscience rebound slightly after sales of upper respiratory infection tests died along with the Swine Flu scare last year.
By Mary Vanac
Meridian Bioscience CEO Jack Kraeutler on how his diagnostics company is making the big jump into molecular tests for bacteria.
By Mary Vanac
Meridian Bioscience's first-quarter sales rise 24 percent to $43 million; net earnings rise 11 percent to $9 million.
Meridian Bioscience Inc. posted first-quarter sales of $42.5 million for the three months ended Dec. 31, 2009, up 23.8 percent compared with $34.3 million during the same period in fiscal 2009. Net earnings rose 10.5 percent to $8.9 million, compared with $8.1 million during Q1 2009:
Press Release
CINCINNATI--(BUSINESS WIRE)--Meridian Bioscience, Inc. (NASDAQ: VIVO):
GENERAL HIGHLIGHTS
Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) today:
